258 Chapter 11 References 1. WHO Regional Office for Europe/European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2022 – 2020 data. Copenhagen: WHO Regional Office for Europe; 2022. 2. Souverein, D., et al., Costs and Benefits Associated with the MRSA Search and Destroy Policy in a Hospital in the Region Kennemerland, The Netherlands. PLoS One, 2016. 11(2): p. e0148175. 3. Vos, M.C., et al., 5 years of experience implementing a methicillin-resistant Staphylococcus aureus search and destroy policy at the largest university medical center in the Netherlands. Infect Control Hosp Epidemiol, 2009. 30(10): p. 977-84. 4. Gardner, E.M., et al., The spectrum of engagement in HIV care and its relevance to testand-treat strategies for prevention of HIV infection. Clin Infect Dis, 2011. 52(6): p. 793800. 5. Nosyk, B., et al., The cascade of HIV care in British Columbia, Canada, 1996-2011: a population-based retrospective cohort study. Lancet Infect Dis, 2014. 14(1): p. 40-49. 6. Duerden, B., et al., The Control of Methicillin-Resistant Staphylococcus aureus Blood Stream Infections in England. Open Forum Infect Dis, 2015. 2(2): p. ofv035. 7. Dagher, M., et al., A Narrative Review of Early Oral Stepdown Therapy for the Treatment of Uncomplicated Staphylococcus aureus Bacteremia: Yay or Nay? Open Forum Infect Dis, 2020. 7(6): p. ofaa151. 8. Bai, A.D., et al., Staphylococcus aureus bacteraemia mortality: a systematic review and meta-analysis. Clin Microbiol Infect, 2022. 28(8): p. 1076-1084. 9. Lawton, J.S., et al., 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol, 2022. 79(2): p. e21-e129. 10. 1Benjamin, E.J., et al., Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation, 2018. 137(12): p. e67-e492. 11. Tong, S.Y.C., et al., The Staphylococcus aureus Network Adaptive Platform Trial Protocol: New Tools for an Old Foe. Clin Infect Dis, 2022. 75(11): p. 2027-2034. 12. Park, S.Y., et al., agr Dysfunction and persistent methicillin-resistant Staphylococcus aureus bacteremia in patients with removed eradicable foci. Infection, 2013. 41(1): p. 1119. 13. Xiong, Y.Q., et al., Phenotypic and genotypic characteristics of persistent methicillinresistant Staphylococcus aureus bacteremia in vitro and in an experimental endocarditis model. J Infect Dis, 2009. 199(2): p. 201-8. 14. Neuner, E.A., et al., Clinical, microbiologic, and genetic determinants of persistent methicillin-resistant Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis, 2010. 67(3): p. 228-33. 15. Holland, T.L., A.S. Bayer, and V.G. Fowler, Persistent MRSA Bacteremia: Resetting the Clock for Optimal Management. Clin Infect Dis, 2022. 16. van Hal, S.J., et al., Predictors of mortality in Staphylococcus aureus Bacteremia. Clin Microbiol Rev, 2012. 25(2): p. 362-86.
RkJQdWJsaXNoZXIy MTk4NDMw